Hans Küpper

IMI Intelligent Medical Implants is a medical technology company. The goal of the company is to develop and market an intelligent retinal implant system for degenerative retinal disorders such as Retinitis Pigmentosa or Macular Degeneration and thereby make a contribution to the improvement of the quality of life of blind people. Through the combination of innovative technology from the medical device, IT and micro systems fields, a new class of active medical products has been created allowing, amongst other things, blind people to regain modest visual perception. The company was founded in 2002 and has 30 employees. The company has a process oriented quality management system in accordance with ISO 13485.

SAZ Stahlanarbeitungszentrun Dortmund GmbH & Co. KG is a steel processing company located in Dortmund, DE. SAZ Stahlanarbeitungszentrun Dortmund is a certified wage processing private company with around 100 employees, specializing in columns, tables, rollers, and logistics. SAZ Stahlanarbeitungszentrun Dortmund uses online request assistants as a tool for calculating the gap, table, and roller divisions. The German company offers services such as steel training, heater services, long parts/tables roller rolls walks coil repair, and material testing. The company is committed to quality management and is certified according to DIN EN ISO 9001\:2015. The company was founded in 1994 and is led by CEO Hans Küpper.

Microcures, Inc. offers therapeutic platform for precisely controlling the movement of cells. The company was founded by David Sharp and Derek Proudian and is headquartered in Santa Cruz, CA.

The Global Life Science Ventures GmbH is an Independent Venture Capital firm founded in 1996. The Global Life Science Ventures GmbH is headquartered in Munich with additional office in Zug.

Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.

Action Pharma A/S is an R&D-focused biotech company located in the Nordic Medicon Valley area in Copenhagen, Denmark. Action Pharma was founded in 2000 and has a pipeline of 4 drug candidates in different stages of development, plus additional compounds in discovery and early preclinical development. Action Pharma pursues the discovery and development of new drugs and treatment concepts to treat cardiovascular diseases, inflammatory diseases and metabolic diseases, such as type-II diabetes and obesity. Its drug candidates are modified endogenous peptides with improved efficacy and small chemical entities targeted the melanocortin receptors. In disease models, its drug candidates have shown strong effects in treating and preventing inflammation and organ damage in conditions such as post-surgical organ dysfunction and acute myocardial infarction. A major focus for Action Pharma is treatment candidates for type-II diabetes, obesity and metabolic syndrome. Moreover, several drug candidates have shown effects in treating inflammatory diseases, such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis and dermatitis.

Pieris AG develops and markets Anticalin-brand proteins. The firm specializes in the research and development of its Anticalin technology, with focus on deriving therapeutic proteins from human lipocalins. It focuses on solving pharmacological and pharmaceutical limitations of both protein- and non-protein-based drug platforms. It offers a pipeline of Anticalin therapeutics that has active and multi-program research and development collaborations with biopharmaceutical companies. The company was founded by Arne Skerra, Steffen Schlehuber, and Claus Schalper in 2001 and is headquartered in Freising, Germany.